Top-line results from the RELIANCE I study showed the candidate missed its primary endpoint, statistically significant improvement in depression symptoms compared to placebo acoording to the Montgomery-Asberg Depression Rating Scale (MADRS).
REL-1017 is under investigation as an adjunct to standard antidepressants.
As in the RELIANCE III trial that reported in October, there were two study sites where the placebo significantly outperformed the treatment arm.
